Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1785-1786, 1997;
This Article
Right arrow Full Text
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gosselin, R. C.
Right arrow Articles by Branch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gosselin, R. C.
Right arrow Articles by Branch, J.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Oak Ridge Conference
Right arrow Hemostasis and Thrombosis
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1997;43:1785-1786.)
© 1997 American Association for Clinical Chemistry, Inc.

Oak Ridge Poster Sessions

Monitoring Oral Anticoagulant Therapy with Point-of-Care Devices: Correlations and Caveats.

R. C. Gosselina, J. T. Owings, E. Larkin, R. H. White, R. Hutchinson and J. Branch

a author for correspondence: fax 916-734-3320, e-mail bgosselli@clb.ucdmc. ucdavis.edu

Utilization of point-of-care (POC) devices for monitoring patients receiving oral anticoagulant therapy is increasing. In this study, we compared three different POC devices with the clinical laboratory method of determining prothrombin times (PT) and the associated International Normalized Ratio (INR).

After approval by our Institutional Review Board, we obtained consent from and enrolled 40 consecutive patients. All patients had documented stabilization of their INR, and patients who had been taking coumadin <7 days were excluded. Whole-blood fingerstick samples were acquired by a single nurse practitioner (R.H.) and tested on the Coumatrak PT monitor (Boehringer Mannheim). Samples were then drawn from the patients by antecubital phlebotomy with a 20-gauge butterfly needle and syringe. The peripherally drawn whole blood was immediately (within 15 s of phlebotomy) tested on the Coumatrak and CoaguChek Plus (Boehringer Mannheim) monitors. The residual blood was then anticoagulated by placing into 32 g/L sodium citrate-containing tubes (Becton Dickinson), and the citrated whole blood was immediately tested on the . . . [Full Text of this Article]


Footnotes


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.